Vor Biopharma earnings update and what it means for investors

Vor Biopharma (VOR) shares are in focus after the company reported second quarter and first half 2026 results, giving investors fresh detail on the scale of its ongoing losses.

The company reported a net loss of US$62.81 million for the second quarter, with basic loss per share from continuing operations of US$1.16. For the six months ended June 30, 2026, Vor Biopharma recorded a net loss of US$282.39 million and a basic loss per share from continuing operations of US$5.80.

These figures follow much larger reported losses in the prior year period, when net loss was US$1,573.67 million for the second quarter and US$1,606.16 million for the first six months, with basic loss per share from continuing operations of US$251.24 and US$256.88 respectively.

Vor Biopharma’s latest earnings update comes after a sharp share price run, with a 30 day share price return of 17.91% and a 90 day gain of 61.06%. However, the 1 year total shareholder return is still down 44.88%, which signals short term momentum building off a weak longer term base.

If you are weighing the risks and potential rewards in early stage biotech, it can help to compare against a wider peer group using a focused screener such as 40 healthcare AI stocks

Vor Biopharma trades at a steep discount to analyst targets after a sharp rebound. The market may still be pricing in its heavy losses and long road ahead. Does that caution look excessive once the valuation is unpacked?

Price-to-earnings of 2.1x for Vor Biopharma: Is it justified?

Vor Biopharma trades on a P/E of 2.1x, which is low compared to both peers and the wider US market based on the latest Simply Wall St checks.

The P/E multiple compares the company’s share price with its earnings per share. For a clinical stage biopharma such as Vor Biopharma, this metric can be tricky because earnings can be volatile and revenue is currently reported as $0, yet the company has recently moved into profitability.

Simply Wall St’s assessment flags Vor Biopharma as trading at good value relative to peers and the US Biotechs industry. The P/E of 2.1x is also well below the estimated fair P/E of 11.3x that the SWS fair ratio model suggests the market could move towards if conditions align.

Result: Price-to-earnings of 2.1x (UNDERVALUED)

However, Vor Biopharma’s ongoing losses and the lack of current revenue mean that any setback in clinical progress or funding plans could quickly challenge this valuation story.

Next Steps

The mixed picture on Vor Biopharma will mean different things to different investors, so it is worth checking the latest data and forming your own view quickly. To weigh those trade offs in detail, review the 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Vor Biopharma?

If Vor Biopharma has your attention, do not stop there. Broaden your watchlist now so you are not relying on a single story to shape your portfolio.

• Target potential mispricing by scanning companies that combine strong fundamentals with attractive valuations using the 49 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses that pair financial strength with lower risk profiles through the 74 resilient stocks with low risk scores.
• Spot early opportunities before the crowd by running the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.